The cushioning beads are prepared by extrusion-spheronization, followed by freeze-drying.
Pellets may be conveniently prepared via extrusion/spheronization.
The enteric pellet is prepared by fluid-bed method or extrusion-spheronization method.
The pharmaceutical beadlet or pellet is manufacture by extrusion and spheronization method.
Extended dosage forms of stavudine are provided comprising beadlets formed by extrusion-spheronization and coated with a seal coating.
The spheroids are obtained by an extrusion and spheronisation process.
The beadlets are prepared from a dry blend of stavudine, a spheronizing agent, a suitable diluent and a stabilizing amount of magnesium stearate.
The composition is useful as a spheronizing agent for producing spheroids of uniform size and sphericity and having high drug loadings.
Sustained release spherical or non-spherical pellets comprising (a) an active ingredient (b) a wax-like agent, and (c) a spheronizing agent are provided.
The composition is preferably formulated in the form of microspheres produced using an extrusion and spheronisation method, and then grouped together in capsules.
According to the invention glyceryl monostearate and a polymeric binder are employed as a spheronising aid in the manufacture of pharmaceutical spheroids containing no or substantially no microcrystalline cellulose.
Sustained release compositions in tablet or multiparticulate forms comprising (a) an active ingredient, (b) a zein, (c) a wax-like agent, and (d) a bulking or spheronizing agent are provided.
The spheroids comprise at least one active pharmaceutical ingredient, a spheronizing aid material and a solid Polyethylene glycol (PEG) with mean molecular weight (MW) of over 1,000.